Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Gilbert Honigfeld"'
Autor:
Swigar, Mary E.
Publikováno v:
American Scientist, 1974 May 01. 62(3), 362-362.
Externí odkaz:
https://www.jstor.org/stable/27844936
Autor:
Gilbert Honigfeld, Gil Golden
Publikováno v:
Clinical Drug Investigation. 28:231-239
Background: This study compared the bioequivalence of FazaClo® (clozapine orally disintegrating tablets) 100 mg to Clozaril® (clozapine standard oral tablets) 100 mg after multiple doses in patients with schizophrenia. Methods: This was a randomize
Autor:
Miles L. Crismon, Francis Hsuan, William T. Robinson, Richard Wagner, Miles G. Choc, Stephen R. Saklad, Gilbert Honigfeld, Larry Ereshefsky, Jack Hirschowitz
Publikováno v:
Pharmaceutical Research. :347-351
Clozapine plasma levels were monitored in 16 patients during a series of three consecutive treatments (single dose-multiple dose-single dose). Each patient received a single 75-mg dose (3 x 25 mg) with clozapine tablets, and serial plasma samples wer
Autor:
Gilbert Honigfeld
Publikováno v:
The Journal of Clinical Psychiatry. 61:63-64
Autor:
Gilbert Honigfeld, John Patin
Publikováno v:
Hospitalcommunity psychiatry. 41(8)
The long-term efficacy of clozapine therapy and its effect on health care costs were examined over a two-year period. Patients on clozapine showed marked clinical improvement as measured by the Brief Psychiatric Rating Scale. They also had significan
Determining the true costs of bed-and-board for the seriously mentally ill. I. Psychiatric hospitals
Autor:
Gilbert Honigfeld
Publikováno v:
Schizophrenia Research. 24:223-224
Autor:
Honigfeld, Gilbert
Publikováno v:
Waterways; Oct2023, Vol. 44 Issue 4, p10-10, 1p
Publikováno v:
Neurology. 41:369-369
Clozapine is an atypical antipsychotic drug with minimal extrapyramidal toxicity recently approved by the Food and Drug Administration for hard-to-treat schizophrenic patients. We reviewed information on 1,418 patients treated with clozapine in the U
Publikováno v:
Archives of General Psychiatry. 47:189
In Reply.— Drs Osser and Albert have essentially raised three questions. First, how should clinicians and researchers define "treatment resistant"? Second, is it useful clinically or heuristically to distinguish lack of adequate response to neurole
Publikováno v:
Psychopharmacology. 99:S60-S63